Provided by Tiger Trade Technology Pte. Ltd.

Agios Pharmaceuticals

31.87
-0.0500-0.16%
Volume:292.45K
Turnover:9.32M
Market Cap:1.90B
PE:-4.55
High:32.15
Open:31.85
Low:31.53
Close:31.92
52wk High:46.00
52wk Low:22.24
Shares:59.47M
Float Shares:50.09M
Volume Ratio:0.38
T/O Rate:0.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.0075
EPS(LYR):-7.1203
ROE:-34.34%
ROA:-22.24%
PB:1.85
PE(LYR):-4.48

Loading ...

Agios Enters Exclusive Global License Agreement With Oscotec to Develop and Commercialize Next-Generation Syk Inhibitor Cevidoplenib

THOMSON REUTERS
·
Jun 01

Agios Pharmaceuticals Is Maintained at Buy by B of A Securities

Dow Jones
·
May 30

Analysts Offer Insights on Healthcare Companies: Becton Dickinson (BDX), Agios Pharma (AGIO) and Healthequity (HQY)

TIPRANKS
·
May 30

Agios Pharmaceuticals price target lowered to $40 from $41 at BofA

TIPRANKS
·
May 29

BUZZ-U.S. STOCKS ON THE MOVE-Tempus AI, SOLV Energy, Replimune

Reuters
·
May 29

BRIEF-Agios Provides Update On Phase 2B Trial Of Tebapivat In Lower-Risk Myelodysplastic Syndromes

Reuters
·
May 29

BUZZ-U.S. STOCKS ON THE MOVE-Costco, Firefly Aerospace, Agios

Reuters
·
May 29

Agios Pharma Won't Advance Tebapivat for Lower-Risk Myelodysplastic Syndromes

Dow Jones
·
May 29

Agios Halts Development of Tebapivat in Lower-Risk MDS After Mid-Stage Trial Miss; Shares Drop Premarket

MT Newswires Live
·
May 29

Agios will not advance tebapivat in lower-risk myelodysplastic syndromes

TIPRANKS
·
May 29

Agios Pharmaceuticals Shares Fall 19% Premarket After Co to Stop Development of Its Blood Disorder Drug

THOMSON REUTERS
·
May 29

Agios scraps blood disorder drug program after study miss

Reuters
·
May 29

Agios Pharmaceuticals - Tebapivat Phase 2 Trial in Sickle Cell Disease Topline Data Expected Second Half 2026

THOMSON REUTERS
·
May 29

Agios Pharmaceuticals - Phase 2B Trial Results for Tebapivat in Lr-Mds Did Not Meet Predefined Threshold

THOMSON REUTERS
·
May 29

Agios Pharmaceuticals - Tebapivat Well Tolerated With No New Safety Signals Identified

THOMSON REUTERS
·
May 29

Agios Pharmaceuticals - Will Not Advance Tebapivat in Lower-Risk Myelodysplastic Syndromes

THOMSON REUTERS
·
May 29

Analysts Offer Insights on Healthcare Companies: Clinuvel Pharmaceuticals (OtherCLVLF) and Agios Pharma (AGIO)

TIPRANKS
·
May 25

Will EU Thalassemia Approval for PYRUKYND Redefine Agios Pharmaceuticals' (AGIO) Mitapivat-Centric Investment Narrative?

Simply Wall St.
·
May 25

Analysts Are Bullish on These Healthcare Stocks: Bicara Therapeutics Inc. (BCAX), Agios Pharma (AGIO)

TIPRANKS
·
May 23

BRIEF-Avanzanite Bioscience’S Partner Agios Announces Pyrukynd® (Mitapivat) Approval In EU

Reuters
·
May 22